Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 vs Standard Chemotherapy in Newly Diagnosed AML
NCT03897127Phase 3Active, not recruiting
- Sponsor
- Ulm University
- Start
- Sep 2019
- Primary completion
- Jun 2027
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML) (2 arms), sponsored by Ulm University. Primary endpoint: Overall Survival at 2 years. Started Sep 2019; status: active, not recruiting.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03897127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03897127.